Protease Inhibitors (PIs)

Safety of Atazanavir in Patients with HIV/HCV or HIV/HBV Coinfection - 9/12/06

Resistance Profile After Treatment with Atazanavir-containing Regimens - 9/08/06

A Summary of the Tipranavir US Expanded Access Program - 9/08/06

Switching from Lopinavir/Ritonavir to Unboosted Atazanavir Lowers Lipids - 9/01/06

Effects of Efavirenz- and Atazanavir-based Regimens on HDL Cholesterol - 8/29/06

Economic and Clinical Impact of Using Atazanavir + Ritonavir versus Lopinavir/Ritonavir- 8/25/06

The ´´95% Adherence Rule´´ May Not Apply to Lopinavir/Ritonavir (Kaletra)- based HAART Regimens - 8/25/06

Lopinavir Concentrations Do Not Differ between African-Americans and Caucasians- 8/25/06

Boosted Lopinavir/Ritonavir plus Saquinavir without Additional Anti-HIV Therapy - 8/25/06

Comparison of NRTI-, NNRTI, and PI-sparing Regimens for First-line Therapy  - 8/25/06

Atazanavir/Ritonavir versus Efavirenz: Retrospective Review of a Large US Cohort  - 8/22/06

Treatment with Atazanavir with or without Ritonavir Results in Clinically Important Improvements in Health-related Quality of Life  - 8/22/06

Selection of Protease Inhibitor-Resistance Mutations During Failure of Lopinavir/ritonavir Monotherapy  - 8/22/06

A Two-year Trial of Lopinavir/Ritonavir Monotherapy after Induction Treatment Compared to Efavirenz-based HAART   - 8/18/06

48-Week Analysis of Lopinavir/Ritonavir Monotherapy Compared to LPV/r + Zidovudine/Lamivudine   - 8/18/06

Lopinavir/Ritonavir as Single-drug Maintenance Therapy in Patients with HIV Suppression   - 8/18/06

Drug Interactions between Brecanavir and other HIV Protease Inhibitors  - 8/15/06

See also Boosted PIs